0.17
+0.0061(+3.70%)
Currency In USD
| Previous Close | 0.17 |
| Open | 0.16 |
| Day High | 0.2 |
| Day Low | 0.16 |
| 52-Week High | 2.19 |
| 52-Week Low | 0.1 |
| Volume | 66,856 |
| Average Volume | 3.82M |
| Market Cap | 7.75M |
| PE | -0.08 |
| EPS | -2.27 |
| Moving Average 50 Days | 0.19 |
| Moving Average 200 Days | 0.48 |
| Change | 0.01 |
If you invested $1000 in NKGen Biotech, Inc. Common Stock (NKGN) since IPO date, it would be worth $29.96 as of May 10, 2025 at a share price of $0.171. Whereas If you bought $1000 worth of NKGen Biotech, Inc. Common Stock (NKGN) shares 1 year ago, it would be worth $135.79 as of May 10, 2025 at a share price of $0.171.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
NKGen Biotech Chairman & CEO Paul Y. Song, M.D., Personally Invests $2.65 Million Cash to Accelerate Phase 2 Clinical Trial and Fulfill Financial Reporting Obligations
GlobeNewswire Inc.
May 08, 2025 12:05 PM GMT
New funding from Dr. Song augments $3.0 million in funding advances from AlpineBrook Capital in 2025 above and beyond the $5.5 million proceeds and additional $4 million commitments in previously-disclosed AlpineBrook convertible notes. SANTA ANA, Ca
NKGen Biotech to Present Troculeucel Clinical and Biomarker Results at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting
GlobeNewswire Inc.
May 07, 2025 12:00 PM GMT
SANTA ANA, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural
NKGen Biotech To Present on the Use of Troculeucel for Alzheimer’s and Parkinson’s Disease at the 7th China International Biotechnology Conference & Exhibition
GlobeNewswire Inc.
Apr 14, 2025 12:00 PM GMT
SANTA ANA, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natura